Your browser is no longer supported. Please, upgrade your browser.
Settings
ALIM Alimera Sciences, Inc. daily Stock Chart
ALIM [NASD]
Alimera Sciences, Inc.
Index- P/E- EPS (ttm)-0.66 Insider Own1.10% Shs Outstand64.93M Perf Week-3.92%
Market Cap95.44M Forward P/E5.72 EPS next Y0.26 Insider Trans-9.07% Shs Float63.84M Perf Month19.51%
Income-33.20M PEG- EPS next Q-0.08 Inst Own80.60% Short Float1.66% Perf Quarter36.11%
Sales34.30M P/S2.78 EPS this Y8.90% Inst Trans7.70% Short Ratio1.66 Perf Half Y-9.82%
Book/sh-0.67 P/B- EPS next Y336.40% ROA-49.90% Target Price5.33 Perf Year-10.91%
Cash/sh0.48 P/C3.08 EPS next 5Y- ROE69.50% 52W Range1.01 - 5.15 Perf YTD36.11%
Dividend- P/FCF- EPS past 5Y2.60% ROI318.60% 52W High-71.46% Beta2.16
Dividend %- Quick Ratio5.10 Sales past 5Y- Gross Margin93.20% 52W Low45.54% ATR0.11
Employees125 Current Ratio5.20 Sales Q/Q84.50% Oper. Margin-88.40% RSI (14)56.34 Volatility7.36% 7.65%
OptionableYes Debt/Eq- EPS Q/Q62.00% Profit Margin-96.60% Rel Volume0.78 Prev Close1.44
ShortableYes LT Debt/Eq- EarningsMar 01 AMC Payout- Avg Volume639.40K Price1.47
Recom2.30 SMA204.63% SMA5014.84% SMA2007.96% Volume498,347 Change2.08%
Nov-17-14Initiated Summer Street Research Buy $12
Sep-29-14Reiterated Northland Capital Outperform $7 → $10
Oct-28-13Upgrade Cowen Market Perform → Outperform
Oct-08-13Initiated Northland Capital Outperform $5
Nov-14-11Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Dec-27-10Reiterated Oppenheimer Outperform $16 → $14
Oct-11-10Initiated Rodman & Renshaw Mkt Outperform $13
Jun-02-10Initiated Oppenheimer Outperform $16
Mar-20-17 09:02AM  Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
Mar-14-17 02:47PM  Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
08:20AM  Alimera Sciences, Inc. (ALIM) Looks Good: Stock Up 12.8%
Mar-13-17 07:30AM  Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in Spain GlobeNewswire +12.77%
Mar-09-17 01:04PM  ALIMERA SCIENCES INC Financials
Mar-07-17 07:30AM  Alimera Sciences to Present at the 29th Annual ROTH Conference GlobeNewswire
Mar-03-17 04:23PM  ALIMERA SCIENCES INC Files SEC form 10-K, Annual Report
10:05AM  Alimera Sciences to Present at the 37th Annual Cowen Health Care Conference GlobeNewswire
Mar-02-17 04:21PM  Edited Transcript of ALIM earnings conference call or presentation 2-Mar-17 3:00pm GMT
05:03AM  Alimera Sciences reports 4Q loss
Mar-01-17 05:08PM  ALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
04:00PM  Alimera Sciences Reports Record Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 Alimera Sciences Inc Earnings Release - After Market Close
Feb-23-17 11:24AM  Alimera Sciences to Report Fourth Quarter 2016 Financial Results on March 1, 2017 GlobeNewswire
Feb-22-17 08:00AM  Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien® in Canada GlobeNewswire
08:00AM  Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien(R) in Canada Marketwired
Feb-06-17 09:00AM  Alimera Sciences Announces the Reimbursement of ILUVIEN® in Italy GlobeNewswire
Jan-11-17 12:33PM  ETFs with exposure to Alimera Sciences, Inc. : January 11, 2017
Dec-18-16 11:35AM  Is Alimera Sciences Inc (ALIM) A Good Stock To Buy? at Insider Monkey
Dec-16-16 11:05AM  ETFs with exposure to Alimera Sciences, Inc. : December 16, 2016
Dec-06-16 10:56AM  ETFs with exposure to Alimera Sciences, Inc. : December 6, 2016
Nov-16-16 05:18PM  ALIMERA SCIENCES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Nov-14-16 12:49PM  ETFs with exposure to Alimera Sciences, Inc. : November 14, 2016
Nov-04-16 04:10PM  ALIMERA SCIENCES INC Files SEC form 10-Q, Quarterly Report
11:58AM  Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 4, 2016
Nov-03-16 11:57PM  Edited Transcript of ALIM earnings conference call or presentation 3-Nov-16 2:00pm GMT -5.79%
11:50AM  ETFs with exposure to Alimera Sciences, Inc. : November 3, 2016
09:07AM  ALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition
05:07AM  Alimera Sciences reports 3Q loss
Nov-02-16 04:36PM  Alimera Sciences Announces Third Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
07:07AM  Q3 2016 Alimera Sciences Inc Earnings Release - After Market Close
Oct-26-16 07:30AM  Alimera Sciences Begins Selling ILUVIEN® in the Middle East GlobeNewswire
Oct-25-16 12:36PM  Alimera Sciences to Report Third Quarter 2016 Financial Results on November 2, 2016 GlobeNewswire
Oct-20-16 05:06PM  ALIMERA SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial O
04:42PM  Alimera Sciences Strengthens Financial Position GlobeNewswire
09:29AM  ETFs with exposure to Alimera Sciences, Inc. : October 20, 2016
Oct-05-16 10:03AM  ETFs with exposure to Alimera Sciences, Inc. : October 5, 2016
Sep-20-16 10:02AM  ETFs with exposure to Alimera Sciences, Inc. : September 20, 2016
Sep-06-16 08:00AM  Alimera Sciences Announces 23 Clinical Presentations and a Sponsored Symposium at 16th EURETINA Congress GlobeNewswire
Aug-23-16 09:00AM  Alimera Sciences Inc (ALIM): Great Point Partners Reveals 5.12% Stake at Insider Monkey
Aug-16-16 04:01PM  Alimera Sciences Announces Exercise of Underwriters Over-Allotment Option and Closing of $26.5 Million Offering of Common Stock GlobeNewswire
Aug-12-16 02:06PM  ETFs with exposure to Alimera Sciences, Inc. : August 12, 2016
Aug-11-16 11:11AM  Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016
09:40AM  ALIMERA SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events
08:41AM  Alimera Sciences Prices Public Offering of Common Stock GlobeNewswire
Aug-10-16 04:05PM  ALIMERA SCIENCES INC Files SEC form 8-K, Other Events -6.86%
04:01PM  Alimera Sciences Proposes Public Offering of Common Stock GlobeNewswire
Aug-09-16 07:30AM  Alimera Sciences announces clinical presentations and sponsored Symposia at ASRS 2016 Annual meeting GlobeNewswire
Aug-05-16 06:05PM  Edited Transcript of ALIM earnings conference call or presentation 4-Aug-16 2:00pm GMT
05:17PM  ALIMERA SCIENCES INC Files SEC form 10-Q, Quarterly Report
Aug-04-16 06:59AM  Alimera Sciences reports 2Q loss -12.00%
06:07AM  ALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition
Aug-03-16 05:41PM  Alimera Sciences Announces Second Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
07:07AM  Q2 2016 Alimera Sciences Inc Earnings Release - After Market Close
Jul-31-16 07:04PM  Tempur Sealy (TPX), GrubHub (GRUB), United States Steel Corporation (X) Among Top Weekly Gainers at Insider Monkey
Jul-27-16 09:57AM  Alimera Sciences (ALIM) Shares March Higher, Can It Continue?
Jul-26-16 07:35AM  ALIMERA SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Financ +59.43%
07:30AM  Alimera Sciences Pre-Announces Record Second Quarter 2016 Revenue GlobeNewswire
Jul-22-16 09:04AM  Alimera Sciences (ALIM) Is in Oversold Territory: What's Next?
Jul-20-16 12:08PM  ETFs with exposure to Alimera Sciences, Inc. : July 20, 2016
Jul-12-16 08:36AM  ALIMERA SCIENCES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -5.93%
Jul-06-16 02:01PM  Alimera Sciences to Present at the Cantor Fitzgerald Conference GlobeNewswire
Jun-27-16 05:03PM  ALIMERA SCIENCES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -7.14%
Jun-02-16 07:00AM  Alimera Sciences to Present at the LD Micro Invitational Conference GlobeNewswire
May-27-16 04:06PM  ALIMERA SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit
May-23-16 04:00PM  Real World Data In Europe Show Majority Of Diabetic Macular Edema Patients Gain Or Maintain Vision With Iluvien® At 12 Months GlobeNewswire
May-19-16 06:55PM  ETFs with exposure to Alimera Sciences, Inc. : May 19, 2016
May-18-16 01:16PM  Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q1, 2016 By the Numbers
May-17-16 07:30AM  Alimera Sciences to Present at the UBS Global Healthcare Conference GlobeNewswire
May-11-16 07:30AM  Alimera Sciences' ILUVIEN® Data Presented at SFO 2016 GlobeNewswire
May-06-16 04:22PM  Edited Transcript of ALIM earnings conference call or presentation 5-May-16 2:00pm GMT
04:11PM  ALIMERA SCIENCES INC Files SEC form 10-Q, Quarterly Report
07:30AM  Alimera Sciences' ILUVIEN® Data Presented At 2016 ARVO PR Newswire
May-05-16 08:05AM  ALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition -13.12%
May-04-16 07:48PM  Alimera Sciences reports 1Q loss AP
04:24PM  Alimera Sciences Announces First Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q1 2016 Alimera Sciences Inc Earnings Release - After Market Close CCBN
Apr-27-16 09:01AM  Stonegate Capital Partners Initiates Coverage on Alimera Sciences Accesswire
Apr-26-16 09:58AM  Alimera Sciences to Report First Quarter 2016 Financial Results on May 4, 2016 GlobeNewswire
Apr-18-16 07:42AM  New Strong Sell Stocks for April 18th
Apr-12-16 09:52AM  New Strong Sell Stocks for April 12th
Mar-31-16 08:37AM  New Strong Sell Stocks for March 31st
Mar-21-16 10:05AM  New Strong Sell Stocks for March 21st
Mar-16-16 08:29AM  New Strong Sell Stocks for March 16th
Mar-15-16 04:06PM  ALIMERA SCIENCES INC Files SEC form 10-K, Annual Report
Mar-14-16 05:00PM  ALIMERA SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial O
Mar-08-16 04:08PM  ALIMERA SCIENCES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -5.76%
Mar-07-16 05:03PM  ALIMERA SCIENCES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
09:47AM  New Strong Sell Stocks for March 7th
Mar-03-16 01:18PM  Edited Transcript of ALIM earnings conference call or presentation 3-Mar-16 3:00pm GMT -16.28%
06:11AM  ALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition
05:03AM  Alimera Sciences reports 4Q loss
Mar-02-16 07:48PM  Alimera Sciences Reports Record Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
07:07AM  Q4 2015 Alimera Sciences Inc Earnings Release - After Market Close
Feb-29-16 07:30AM  Alimera Sciences to Present at 36th Annual Cowen Healthcare Conference
Feb-18-16 07:30AM  Alimera Sciences to Report Fourth Quarter 2015 Financial Results on March 2, 2016 GlobeNewswire
Feb-05-16 04:44PM  ALIMERA SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement -7.17%
Jan-04-16 07:30AM  Alimera Sciences Announces ILUVIEN® J Code J7313 Is Now Active PR Newswire
Dec-23-15 12:51PM  Alimera Sciences, Inc. Earnings Analysis: Q3, 2015 By the Numbers
Dec-15-15 07:30AM  Alimera Sciences Signs Agreement To Distribute ILUVIEN® In The Middle East PR Newswire -5.42%
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, Portugal, and the United Kingdom. The company focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a constant micro-dose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. It has license agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Myers C. DanielCEOMar 10Sale1.3921,17229,429180,861Mar 13 04:56 PM
Roberts Calvin W.DirectorDec 12Sale1.1150,00055,50065,820Dec 14 04:30 PM
Holland DavidSVP of Sales and MarketingOct 11Option Exercise1.3327,97137,201134,389Oct 13 04:13 PM
Myers C. DanielCEOOct 11Option Exercise1.3355,14773,346145,131Oct 13 04:14 PM
Green KennethSVP & Chief Scientific OfficerOct 11Option Exercise1.3344,20858,797136,561Oct 13 04:13 PM
EISWIRTH RICHARD S JRPresident and CFOSep 15Option Exercise1.3351,47168,45686,445Sep 16 04:25 PM
EISWIRTH RICHARD S JRPresident and CFOSep 15Sale1.5151,47177,72634,974Sep 16 04:25 PM
BAVP, L.P.10% OwnerApr 21Sale2.59478,5731,239,4853,998,718Apr 22 08:12 PM
BAVP, L.P.10% OwnerApr 20Sale2.021002024,477,291Apr 22 08:12 PM